Systematic characterization of the expression, prognosis and immune characteristics of PLOD family genes in breast cancer.

Autor:	Wang DD; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Li L; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Fu YQ; Department of Medical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing 210009, China., Yang SJ; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Chen X; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Hou JC; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Zhang Q; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Tian XX; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Tang JH; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Zhang J; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China., Zhang HD; Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Jazyk:	angličtina
Zdroj:	Aging [Aging (Albany NY)] 2024 Jul 26; Vol. 16 (14), pp. 11434-11445. Date of Electronic Publication: 2024 Jul 26.
DOI:	10.18632/aging.206029
Abstrakt:	Background: The expression patterns and prognostic value of Procollagen-lysine, 2-oxoglutarate 5-dioxygenase (PLOD) family genes in breast cancer remain to be elucidated. Methods: The expression levels, prognostic value, and biological function of PLODs were determined using Oncomine, cBioPortal, GEPIA, Timer, UALCAN, PrognoScan, GeneMANIA, Metascape, and breast cancer tissue microarrays. Results: The expressions of PLOD1 and PLOD3 were upregulated in breast cancer tissues, indicating worse clinical stages. High expression levels of PLOD family genes were associated with worse disease-free survival and distant metastasis-free survival, while high expression levels of PLOD1 and PLOD3 were related to worse overall survival in all breast cancer patients. The levels of PLOD family genes were all significantly higher in the age ≤51 y group, HR-negative patients, and triple negative breast cancer (TNBC) patients. They are associated with tumor-infiltrating immune cells (TIICs), including CD4+ T cells, CD8+ T cells, B cells, macrophages, neutrophils, and dendritic cells. According to co-expression gene analysis and functional enrichment, they are associated with protein hydroxylation, collagen biosynthesis and modifying enzymes, collagen metabolism, RNA splicing, extracellular matrix organization, VEGFA-VEGFR2 signaling pathway, and skeletal system development. Immunohistochemistry showed that the expressions of all PLOD family genes were significantly elevated in breast cancer tissues. PLOD1 expression was positively correlated with ER, TNBC status, and tumor grade. PLOD2 expression was positively connected with Ki-67 status. PLOD3 expression was positively related with age and tumor grade. Conclusions: PLOD family genes are novel potential prognostic biomarkers for breast cancer, and targeting PLOD inhibitors might be an effective strategy for breast cancer therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu